Feeds
Doctors thought that combining two newer drugs that more precisely attack cancer would help people with advanced colon cancer. Instead, it made the cancer worse and made the patients more miserable, a study found. The surprising findings underscore the importance of doing rigorous studies before rushing to mix these pricey, new-generation drugs, the Dutch researchers and other experts said.
Medicare has quietly expanded its coverage for cancer drugs to include some treatments that haven't gotten the Food and Drug Administration's full seal of approval.
A combination of two new-generation cancer drugs modestly delayed the time it took for cancer to worsen in a study of 300 women with very advanced disease who had stopped responding to other treatments.
When Jill Bracey Cowley was diagnosed with bone marrow cancer eight years ago, doctors told her she had two years to live. So she decided to take a gamble and try new drugs that hadn't yet been approved.
New Screening Could Lead to More Potent Cancer Drugs Researchers have discovered a way to identify drugs that can specifically attack and kill cancer stem cells, a finding that could lead to a new generation of anticancer drugs and a new strategy of treatment.
Erbitux Boosts Survival in Lung Cancer PatientsErbitux, also known as cetaximub, is designed to block a protein called epidermal growth factor that is believed to play a role in cancer cell growth. The drug was already approved to treat colon cancer in 2004 as well as head and neck tumors in April 2004.
Log In | Register
